Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Federal Trade Commission
US Army
Fuji
Julphar
Baxter
Johnson and Johnson
Dow

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 064103

« Back to Dashboard

NDA 064103 describes CERUBIDINE, which is a drug marketed by Sanofi Aventis Us, West-ward Pharms Int, and Wyeth Ayerst, and is included in three NDAs. Additional details are available on the CERUBIDINE profile page.

The generic ingredient in CERUBIDINE is daunorubicin hydrochloride. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the daunorubicin hydrochloride profile page.
Summary for 064103
Tradename:CERUBIDINE
Applicant:West-ward Pharms Int
Ingredient:daunorubicin hydrochloride
Patents:0
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 20MG BASE/VIAL
Approval Date:Feb 3, 1995TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
UBS
QuintilesIMS
Fuji
Healthtrust
Cantor Fitzgerald
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.